Search company, investor...
Cardiovascular Systems company logo

Cardiovascular Systems

Founded Year




Market Cap


Stock Price




About Cardiovascular Systems

Cardiovascular Systems (NASDAQ: CSII) develops and commercializes interventional treatment systems for vascular disease. The company's goal is to provide physicians with the tools they need to help Americans suffering from peripheral arterial disease (PAD) – blockages in leg arteries – and the potential catastrophic risk of limb amputation. The company's initial product, the Diamondback 360° Orbital Atherectomy System, is a minimally invasive catheter system for treating PAD.

Headquarters Location

1225 Old Highway 8 NW

Saint Paul, Minnesota, 55112,

United States


Missing: Cardiovascular Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cardiovascular Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cardiovascular Systems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardiovascular Systems is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Cardiovascular Systems Patents

Cardiovascular Systems has filed 1 patent.

The 3 most popular patent topics include:

  • Cardiology
  • Vascular diseases
  • Angiology
patents chart

Application Date

Grant Date


Related Topics




Lithics, Truck manufacturers, Sauropods, Upper limb anatomy, Skeletal system


Application Date


Grant Date



Related Topics

Lithics, Truck manufacturers, Sauropods, Upper limb anatomy, Skeletal system



Latest Cardiovascular Systems News

Cardiovascular Systems Releases the 2.00 Max Crown

Nov 18, 2022

Product features an increased 70-micron diamond coated crown that creates more efficient engagement in mixed plaque. Michael Barbella, Managing Editor11.18.22 Cardiovascular Systems Inc.  (CSI) has released its 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown) to the worldwide market. “The full commercial launch of the 2.00 Max Crown represents another important product launch for CSI as we broaden and diversify our product offering," CSI President and CEO Scott R. Ward said. "Our peripheral orbital atherectomy systems can now treat a wider range of plaque morphologies throughout the leg. Combining this new device with our full line of interventional support devices, we continue to advance the ability of physicians to improve outcomes for patients undergoing peripheral interventions.”   Built on the Diamondback 360 Orbital Atherectomy platform, the 2.00 Max Crown is designed to enable simultaneous modification of both intimal and medial calcium. The new 2.00 Max Crown features an increased 70-micron diamond coated crown that creates more efficient engagement in mixed plaque, helping to achieve optimal luminal gain in mild to moderately calcified lesions above the knee. Amit Srivastava, M.D., at Bay Area Heart Center in St. Petersburg, Fla., was one of the first physicians in the U.S. to incorporate the 2.00 Max Crown into his practice. “The new 2.00 Max Crown greatly expands the lesions that can be treated with CSI’s Orbital Atherectomy. This device delivers exceptional luminal gain in mixed morphology lesions above the knee,” he said. Eighteen million to 20 million Americans, most over age 65, suffer from peripheral artery disease (PAD), caused by the accumulation of plaque in peripheral arteries reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates. Based in St. Paul, Minn., CSI develops and commercializes solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. * The 2.00 Max Crown has not been tested to support removal of stenotic material from artificial arteriovenous dialysis fistulae (AV shunt).

Cardiovascular Systems Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cardiovascular Systems Rank

Cardiovascular Systems Frequently Asked Questions (FAQ)

  • When was Cardiovascular Systems founded?

    Cardiovascular Systems was founded in 1989.

  • Where is Cardiovascular Systems's headquarters?

    Cardiovascular Systems's headquarters is located at 1225 Old Highway 8 NW, Saint Paul.

  • What is Cardiovascular Systems's latest funding round?

    Cardiovascular Systems's latest funding round is PIPE.

  • Who are the investors of Cardiovascular Systems?

    Investors of Cardiovascular Systems include Mitsui & Co. Global Investment, Maverick Capital, ITX International, Easton Capital, Lumira Ventures and 3 more.

  • Who are Cardiovascular Systems's competitors?

    Competitors of Cardiovascular Systems include Endologix, Novate Medical, Torax Medical, Magneceutical Health, IDev Technologies and 12 more.

Compare Cardiovascular Systems to Competitors

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

OmniSonics Medical Technologies

OmniSonics was a medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.


Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.